Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
Jianmin Fang, M.D. the CEO of the biotechnology company RemeGen, recently announced in PRNewswire that the company is continuing its significant progress in its research of Telitacicept (RC18) to treat…